NCT07447206Not yet recruitingPhase 2
Vascular Intervention Strategies Trial for Alzheimer's
Vascular Intervention Strategies Trial for Alzheimer's (VISTA)
Source: ClinicalTrials.gov · Last updated 4 May 2026
Brief summary (registry, in English)
The proposed pharmacist-led study is a feasibility pilot trial for the management of vascular risk factors of hypertension and hypercholesterolemia in 10 APOE ε4 carriers, 50-75, at-risk for dementia. All participants will receive angiotensin receptor blockers (ARBs) for high blood pressure, and hydrophilic statins (or a non-statin alternative) for high cholesterol over a six-month period.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 25 Feb 2026
- Start date
- 1 May 2026
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- University of Southern California
- NCT number
- NCT07447206
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 10
- From 1 May 2026 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindications to blood pressure and cholesterol lowering medications
- Receiving palliative or hospice care
- Receiving chronic opioid therapy
- Organ transplant
- Concurrent participation in another clinical trial
Other illness
- Use of medications prescribed for dementia (e.g., aducanumab, donanemab, lecanemab, donepezil, galantamine, rivastigmine, memantine)
- Evidence of dementia based on medical record review
- Bipolar illness or schizophrenia
- Drug or alcohol disorder
- Any significant neurological disease (e.g., Parkinson's disease, amyotrophic lateral sclerosis, or multiple sclerosis)
Lab values
- History of stroke, symptomatic HF or left ventricular ejection fraction \< 35%
- ESRD or eGFR \< 20 ml/min /1.73m2
Other
- One minute standing SBP \< 110 mm Hg
- Arm circumference prevents from accurate BP measurement with use of available devices
- Lost weight of \> 10% unintendedly (within the past 6 months),
- Living in a skilled nursing or rehabilitation facility
- Severe loss of visual, hearing or communication ability
- Does not consent to be contacted or to have their medical record reviewed for research purposes
Who the study is looking for
- APOE ε4 carrier (homozygote or heterozygote)
- LDL-C of 100-250 mg/dL
- Systolic blood Pressure (SBP) 130-180 mm Hg
- Age 50-75 years
- Fluency in English
- No dementia based on medical record review
- Male or post-menopausal female
Age in the registry: 50 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical Sciences Building (CSC) Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.